These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34360010)

  • 1. Indonesia-Based Study of the Clinical and Cost-Saving Benefits of Subcutaneous Allergen Immunotherapy for Children with Allergic Rhinitis in Private Practice.
    Endaryanto A; Nugraha RA
    Cells; 2021 Jul; 10(7):. PubMed ID: 34360010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
    Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
    Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
    Liu Y; Xing Z; Wang J; Geng C
    Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study.
    Suratannon N; Limsuwan T; Tantilipikorn P; Chatchatee P; Saengapaswiriya A; Boonpiyathad T; Thongngarm T; Roongpuvapaht B; Chantaphakul H; Kulalert P; Thanaviratananich S; Sangsupawanich P; Fooanant S; Manuyakorn W; Chusakul S; Piboonpochanun O; Apornpong T; Wongpiyabovorn J; Ruxrungtham K;
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):233-245. PubMed ID: 39417769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
    Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
    Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis.
    Wang N; Song J; Sun SR; Zhu KZ; Li JX; Wang ZC; Guo CL; Xiang WX; Tong YL; Zeng M; Wang H; Xu XY; Yao Y; Liu Z
    Allergy; 2024 May; 79(5):1230-1241. PubMed ID: 38403941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Robust Biomarkers for Early Predicting Efficacy of Subcutaneous Immunotherapy in Children With House Dust Mite-Induced Allergic Rhinitis by Multiple Cytokine Profiling.
    Xie S; Fan R; Tang Q; Cai X; Zhang H; Wang F; Xie S; Gao K; Zhang J; Xie Z; Jiang W
    Front Immunol; 2021; 12():805404. PubMed ID: 35095890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aqueous intradermal low-dose house dust mite immunotherapy in tropical settings: a valid cost-effective approach for developing nations?
    Rondon C; Sánchez-Borges M; Cupello ER; Fabiano F; Capriles-Hulett A
    Allergol Immunopathol (Madr); 2021; 49(2):31-39. PubMed ID: 33641291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization analysis of sublingual immunotherapy versus subcutaneous immunotherapy for house dust mite respiratory allergic disease in Denmark.
    Rønborg S; Johnsen CR; Theilgaard S; Winther A; Hahn-Pedersen J; Andreasen JN; Olsen J
    J Med Econ; 2016 Aug; 19(8):735-41. PubMed ID: 26909663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Immunotherapy for Allergic Asthma in a Single Center of Korea: Efficacy, Safety, and Clinical Response Predictors.
    Lee JH; Kim SC; Choi H; Jung CG; Ban GY; Shin YS; Nahm DH; Park HS; Ye YM
    J Korean Med Sci; 2017 Jul; 32(7):1124-1130. PubMed ID: 28581269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semi-depot house-dust mite allergen extract for Chinese with allergic rhinitis and asthma.
    Li X; Wang X; Lin X; Xu G; Tao Z; Jiang W; Cheng L; Guo Y; Lai H; Shen K
    Am J Rhinol Allergy; 2016 May; 30(3):201-8. PubMed ID: 27216351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented type 2 inflammatory response in allergic rhinitis patients experiencing systemic reactions to house dust mite subcutaneous immunotherapy.
    Ji P; Yang L; Zhu L; Hu L; Wang Y; Shi C; Jiang Q; Huang N; Yang Y; Chen H; Zhu R
    Pediatr Allergy Immunol; 2024 Aug; 35(8):e14207. PubMed ID: 39092594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
    Wang ZX; Shi H
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cost-Minimisation Analysis Comparing Sublingual Immunotherapy to Subcutaneous Immunotherapy for the Treatment of House Dust Mite Allergy in a Swedish Setting.
    Björstad Å; Cardell LO; Hahn-Pedersen J; Svärd M
    Clin Drug Investig; 2017 Jun; 37(6):541-549. PubMed ID: 28326466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy and safety study of standardized mite allergen specific immunotherapy with no reduction during maintenance in children with respiratory allergic disease].
    Liang Y; Zhong Y; Li YY; Zhu LP; Yang LF; Ou SX; Chen ZG; Zhang PP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jun; 58(6):768-777. PubMed ID: 38955723
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety Profile and Issues of Subcutaneous Immunotherapy in the Treatment of Children with Allergic Rhinitis.
    Endaryanto A; Nugraha RA
    Cells; 2022 May; 11(9):. PubMed ID: 35563890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IgE Blocking Activity Induced by Dermatophagoides pteronyssinus Subcutaneous Immunotherapy Does Not Correlate with Specific IgA but with IgG4 in both Serum and Saliva.
    He Y; Liu J; Zhao D; Zhang S; Hao G; Sun Y; Zhong H; Chen H; Würtzen PA; Larsen JN; Lai X
    Int Arch Allergy Immunol; 2021; 182(12):1231-1244. PubMed ID: 34280916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. House dust mite SCIT reduces asthma risk and significantly improves long-term rhinitis and asthma control-A RWE study.
    Jutel M; Klimek L; Richter H; Brüggenjürgen B; Vogelberg C
    Allergy; 2024 Apr; 79(4):1042-1051. PubMed ID: 38429981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of grass pollen subcutaneous immunotherapy (SCIT) compared to sublingual immunotherapy (SLIT) and symptomatic treatment in Austria, Spain, and Switzerland.
    Brüggenjürgen B; Reinhold T
    J Med Econ; 2018 Apr; 21(4):374-381. PubMed ID: 29271271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.